Illumina MiSeq i100 System or equal NOI_OC-2026-132529
Summary
AI-generated · Mar 21, 2026Purchase of a single Whole Genome Sequencing instrument under a sole-source, Firm-Fixed-Price award. The requirement allows the Illumina MiSeq i100 System or an equivalent product that meets all salient characteristics identified in the Statement of Work; proposals for an equivalent must show exactly how each salient characteristic is satisfied, and the instrument must include a minimum one-year warranty covering parts and labor.
Interested parties should submit capability statements demonstrating the ability to meet the requirements, with a clear demonstration of how the proposed equivalent meets each salient characteristic.
NOTICE OF INTENT TO SOLE SOURCE Description This notice is issued for informational and market research purposes only and does not constitute a solicitation. The FDA intends to award a sole source Firm-Fixed-Price purchase order for one (1) Whole Genome Sequencing instrument. The Government is considering the Illumina MiSeq i100 System or equal product that meets all salient characteristics identified in the Statement of Work (SOW). Offerors proposing equal products shall demonstrate how the proposed product meets each of the salient characteristics The instrument shall include a minimum one (1) year manufacturer s warranty covering parts and labor. Response Instructions Interested parties shall submit capability statements demonstrating ability to meet requirements. Offerors proposing an equivalent must clearly demonstrate how requirements are met. Response Deadline March 26, 2026, at 2:30 PM ET Submission Contracting Officer: Iris Johnson Email: Iris.Johnson1@fda.hhs.gov
From Special Notice posted on Mar 20, 2026Notice history
1-
Special Notice LATEST Posted Mar 20, 2026
Details
Award Information
Not yet awarded
Contacts
Phone